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OBJECTIVEdAdverse effects of hypercaloric, high-fructose diets on insulin sensitivity and
lipids in human subjects have been shown repeatedly. The implications of fructose in amounts
close to usual daily consumption, however, have not been well studied. This study assessed the
effect of moderate amounts of fructose and sucrose compared with glucose on glucose and lipid
metabolism.
RESEARCH DESIGN ANDMETHODSdNine healthy, normal-weight male volunteers
(aged 21–25 years) were studied in this double-blind, randomized, cross-over trial. All subjects
consumed four different sweetened beverages (600 mL/day) for 3 weeks each: medium fructose
(MF) at 40 g/day, and high fructose (HF), high glucose (HG), and high sucrose (HS) each at
80 g/day. Euglycemic-hyperinsulinemic clamps with [6,6]-2H2 glucose labeling were used to
measure endogenous glucose production. Lipid proﬁle, glucose, and insulin were measured in
fasting samples.
RESULTSdHepatic suppression of glucose production during the clamp was signiﬁcantly
lower after HF (59.4 6 11.0%) than HG (70.3 6 10.5%, P , 0.05), whereas fasting glucose,
insulin, and C-peptide did not differ between the interventions. Compared with HG, LDL
cholesterol and total cholesterol were signiﬁcantly higher after MF, HF, and HS, and free fatty
acids were signiﬁcantly increased after MF, but not after the two other interventions (P, 0.05).
Subjects’ energy intake during the interventions did not differ signiﬁcantly from baseline
intake.
CONCLUSIONSdThis study clearly shows that moderate amounts of fructose and sucrose
signiﬁcantly alter hepatic insulin sensitivity and lipid metabolism compared with similar
amounts of glucose.
Diabetes Care 36:150–156, 2013
In the U.S., the consumption of fructoseincreased by more than 25% between1970 and 1997 as the total sugar intake
of the population rose (1). During the same
period, the prevalence of obesity rose
dramatically, paralleling the increase in
fructose consumption and the introduc-
tion of high-fructose corn syrup (2).
Whether there is a causal relationship
between those developments, however,
remains unclear. Total fructose consump-
tion from natural and added sources, esti-
mated from food disappearance data, was
estimated to be 97 g/person/day in 1997
in the U.S. (1) and 83 g/person/day in
1998 in Switzerland (3).
Epidemiologic and intervention stud-
ies of fructose and other caloric sweet-
eners have shown detrimental effects on
health. In a cross-sectional study in U.S.
adults, for example, the consumption of
caloric sweeteners was associated with
increased dyslipidemia (4) and in the
Health Professionals Follow-up Study,
high intakes of sugar-sweetened bever-
ages (SSB) increased the risk for type 2
diabetes (5). Intervention trials have pro-
vided evidence that high- to very high–
fructose doses led to increases in de novo
lipogenesis, blood triglycerides, and he-
patic insulin resistance (6–8).
Not all of these studies found consis-
tent effects for all parameters, however. In
the study by Lê et al. (6), where 1.5 g
fructose/kg body weight were consumed
during a 4-week period, fasting lipids and
glucose were affected, but insulin resis-
tance, as determined by a euglycemic-
hyperinsulinemic clamp, did not change.
However, their study only tested fructose,
without comparison with other sugars.
Furthermore, relatively high amounts of
fructose were consumed in most of these
studies, reaching up to 25% of total
energy intake. In a recent intervention
study in healthy Swiss men, we found ad-
verse effects of low to moderate amounts of
fructosedbut also glucose and sucrosed
on fasting glucose and inﬂammatory mark-
ers, whereas only beverages containing
fructose seemed to negatively affect LDL
particle size. Even though fasting glucose
was altered, none of the interventions
showed any effect on glucose tolerance or
on indices of insulin sensitivity calculated
during an oral glucose tolerance test (9).
The aim of the current study was
therefore to assess the effect of moder-
ate amounts of fructose and sucrose, com-
pared with the same amounts of glucose,
speciﬁcally on hepatic insulin sensitivity
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but also on lipid proﬁles of healthy human
subjects using euglycemic-hyperinsulinemic
clamps with [6,6]-2H2 labeled glucose.
RESEARCH DESIGN AND
METHODS
Study design
The study consisted of four different
interventions in random sequence. Each
intervention lasted 3 weeks and was di-
rectly followed by an examination in our
clinic. Thereafter, a washout of a mini-
mum of 4 weeks was implemented before
the next intervention began. The ﬁrst
subject started the study in February
2009, and the last subject completed the
study in March 2011. During each in-
tervention, subjects were supplied with
SSB containing different sugars in differ-
ent concentrations: medium fructose
(MF), 40 g/day; high fructose (HF), 80
g/day; high glucose (HG), 80 g/day; and
high sucrose (HS), 80 g/day. The drinks
were provided in containers of 200 mL
each, with blinded content, and the sub-
jects had to consume three drinks (total,
600 mL) daily. The sugar concentrations
of the drinks were 66.5 g/L for the
medium concentrations and 133.5 g/L
for the high concentrations. Subjects were
advised to consume the drinks together
with the three main meals. To assess
compliance, subjects were asked to return
beverages not consumed on the day of
visit to the metabolic ward.
Thedrinkswereproducedby theNestlé
Product TechnologyCenter in Konolﬁngen,
Switzerland, under good manufacturing
practice conditions and according to our
instructions. Before their use in the study,
the drinks underwent quality control at
the Product Technology Center. During
the study, sugar content of the drinks was
monitored and found to be stable.
The order of the four different inter-
ventions was randomly assigned to the
subjects (physical randomization), and
the study was carried out in a double-
blind manner with intention-to-treat
analysis of the data. The random alloca-
tion of the order of interventions was
implemented by a coworker not other-
wise involved in the study. Participants,
the nurse taking the anthropometric
measurements, and the laboratory tech-
nicians were blinded to the order of
interventions.
Subjects
Nine healthy, normal-weight male volun-
teers (BMI between 20 and 24 kg/m2, age
between 21 and 25 years) living in the
region of Zurich, Switzerland, were in-
cluded in this study. Subjects were re-
cruited through advertisements at
the universities in Zurich by an author
(I.A.). Written informed consent was ob-
tained from all subjects before entering
the study. The study was approved by
the ethics committee of the University
Hospital Zurich.
Sample size calculation was based on
an estimated difference in hepatic suppres-
sion between two interventions of 10%,
with a standard deviation of 6% (a = 0.016
after Bonferroni correction for three com-
parisons), and it was determined a sample
size of nine volunteers would be sufﬁcient.
Volunteers were eligible for the study if
they were male, had a normal BMI (19–
25 kg/m2), were healthy, and aged 20 to
50 years. Volunteers taking regular medi-
cation or consuming SSB with a total car-
bohydrate content exceeding 60 g/day
were not included in the study.
Protocol
One day before each examination, subjects
were asked not to engage in strenuous
physical activity. On the examination day,
they were asked to present at the Clinical
Trials unit of the University Hospital Zur-
ich at 7.30 A.M. after a 12-h overnight fast.
Upon arrival, weight was determined to
the nearest 100 g using a digital balance
(WB 100 P, Tanita, Hoofddorp, the Neth-
erlands), and height was measured to the
nearest 0.5 cm using a wall-mounted sta-
diometer at the ﬁrst examination. BMI was
calculated as weight (kg)/height (m)2.
Waist and hip circumference were deter-
mined using a nonstretchable measuring
tape. Percentage of body fat was measured
by bioelectrical impedance (AKERN BIA
101, AKERN, Pontassieve, Italy) with the
subject supine.
Blood pressure was measured using an
automated device (Omron M6, upper arm
blood pressure monitor) after a 15-min
rest while supine. After this, with the
subjects resting quietly in a bed, an in-
dwelling catheter was inserted into the
vein of the right arm for blood sampling.
Another indwelling catheter was inserted
into an antecubital vein of the left arm for
the infusion of glucose, insulin, and the
tracer ([6,6]-2H2 glucose). In the fasted
state, blood samples were collected for
the measurement of glucose, insulin, C-
peptide, lipid proﬁle, and leptin. After
blood sampling, a primed continuous in-
fusion of [6,6]-2H2 glucose was adminis-
tered during 5 h to determine endogenous
glucose production (bolus of 2 mg/kg over
10 min, followed by a continuous rate of
0.02 mg/kg/min). After 180 min of tracer
equilibration, a hyperinsulinemic-euglyce-
mic clamp was started for the following
120min. Insulin was infused continuously
(bolus of 60 mU/m2/min for 3 min, fol-
lowed by continuous rate of 15 mU/m2/
min). A relatively low insulin infusion
rate with incomplete suppression of he-
patic glucose production was chosen to re-
veal differences in insulin sensitivity in our
generally insulin-sensitive study group and
based on our previous experiences (10).
Blood samples were collected every 5
min during the clamp to monitor blood
glucose concentrations, and glucose
(20% w/v) was infused at variable rates
to keep the blood glucose euglycemic
(;4.5 mmol/L) (Table 2). The 20% glu-
cose infusion contained 1.2% [6,6]-2H2
glucose to maintain a constant plasma
D2-glucose tracer–to–tracee ratio (TTR)
during the clamp. Blood was drawn at
150, 165, and 180 min of the 3-h tracer
equilibration (baseline) period and at 60,
90, 105, and 120 min of the 2-h clamp
period for the determination of tracer con-
centrations (TTR of [6,6]-2H2 glucose).
Glucose kinetics were calculated as de-
scribed previously (11) at near-steady
state at the end of the tracer equilibration
baseline period (150–180 min) and dur-
ing the last 30 min of the clamp (mean
values from time points given above). To-
tal glucose ﬂux (Ra), endogenous glucose
production rate (EGP), glucose metabolic
clearance rate (Rd/glucose concentration,
i.e., insulin mediated glucose disposal, a
standard parameter of whole-body insulin
sensitivity), and percentage of hepatic
suppression of glucose production (a pa-
rameter of hepatic insulin sensitivity) were
calculated as follows:
Ra = F/TTR, with F being the rate of
tracer infusion;
EGP = Ra – glucose infusion rate;
glucosemetabolic clearance rate = Rd/
glucose concentration = Ra/glucose con-
centration; and
hepatic suppression = 100% 3
[(EGPbasal2 EGPclamp)/EGPbasal].
In the week before each examination
and before the start of the ﬁrst inter-
vention, all subjects ﬁlled in a 3-day (2
weekdays and 1 weekend day) weighed
food record (12). During those 3 days,
all foods and drinks consumed had
to be weighed on a digital kitchen
scale whenever possible, and if not pos-
sible, amounts had to be documented
in standard kitchen measures to allow
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quantitative estimation of dietary intake.
Subjects were asked not to change their
usual eating habits during the days of re-
cording.
The individual 3-day food records of
each subject were carefully checked on the
day of the examination to ensure com-
pleteness and comprehensibility. Data
were then entered into the Swiss version of
the EBISpro nutrition software (J. Erhardt,
University of Hohenheim, Germany) to
convert the amount of food eaten into
individual nutrients. The 3-day energy
and nutrient intakes were averaged to
obtain a mean daily energy and nutrient
intake for each subject.
Free fructose and free glucose refer to
fructose and glucose that is contained in
the food as monosaccharide, whereas
total fructose and total glucose refer to
the monosaccharides and also the part
derived from the disaccharide sucrose
(50% fructose and 50% glucose).
The primary outcome measure of this
trial was the change in insulin sensitivity,
determined as the hepatic glucose sup-
pression during the euglycemic-hyperin-
sulinemic clamp after fructose and
sucrose interventions compared with glu-
cose. Secondary outcome measures were
changes in fasting concentrations of lipids,
glucose, insulin, and C-peptide, as well as
changes in anthropometric measures.
Laboratory analysis
Blood glucose was directly measured
from whole blood samples (fasting and
during the clamp) using an automated
enzymatic method (YSI 2300; YSI Life
Sciences, Yellow Springs, OH). The re-
maining blood samples were centrifuged,
and the serum and plasma were directly
processed for the lipid proﬁle or stored at
2208C for further analysis. Triglycerides,
cholesterol, and free fatty acids were
measured in fresh serum on Roche
MODULAR by enzymatic reactions (tri-
glyceride GPO-PAP and cholesterol
CHOP-PAP; Roche Diagnostics, Mann-
heim, Germany), on Roche INTEGRA
by a homogenous enzymatic color reac-
tion (HDL cholesterol plus third genera-
tion; Roche Diagnostics), and on Konelab
(Free Fatty Acids; Thermo Scientiﬁc,
Dreieich, Germany). From frozen serum,
C-peptide was measured using RIA
(IRMA-C-PEP; CIS Bio International,
Bagnols-sur-Cèze Cedex, France) and
leptin using ELISA (EZHL-80 SK; Linco
Research, St. Charles, MO). Plasma
[6,6]-2H2 glucose enrichment (TTR) was
measured by gas chromatography-mass
spectrometry (Hewlett-Packard Instru-
ments, Palo Alto, CA) as described else-
where (13).
Statistical analysis
Statistical analysis was performed using
SPSS 19.0 software (IBM SPSS, Chicago,
IL). All variables were checked for normal
distribution before data analysis. Data are
expressed as arithmetic mean 6 SD for
normally distributed variables and as geo-
metric mean 6 SD for non-normally dis-
tributed data. Non-normally distributed
data were log-transformed, and further
analysis was done using the transformed
data. According to the intention-to-treat
design of the study, all subjects (complet-
ers and noncompleters) were included in
the ﬁnal analysis. The effect of the inter-
ventions and the order of the interven-
tions on anthropometric and metabolic
parameters was examined using multiple
linear regression, as described elsewhere
(14), always controlling for between-
patient differences. Post hoc Bonferroni
correction was applied to account for
multiple comparisons. In the main anal-
ysis, the three other interventions were
compared with the glucose intervention,
and thus, a correction factor of three
(three interventions) was used. For the di-
etary intake, all four interventions were
compared with baseline, and thus, a cor-
rection factor of four was used. A value of
P , 0.05 after correction was considered
signiﬁcant.
RESULTSdNine subjects participated
in the study. Except for one, who was not
able to ﬁnish the last intervention (MF)
because he moved abroad, all subjects
completed all four interventions. At base-
line, the subjects were amean age of 22.86
1.7 years. Their anthropometric character-
istics after each of the interventions are re-
ported in Table 1. Compared with the HG
intervention, body weight, BMI, body fat,
and waist circumference were slightly but
signiﬁcantly lower after the HF interven-
tion (P , 0.05, general linear model with
Bonferroni correction for three compari-
sons). Body weight and BMI were also sig-
niﬁcantly lower after the MF intervention
compared with HG (P , 0.01).
The results of the euglycemic-hyper-
insulinemic clamps after each intervention
are reported in Table 2. The hepatic sup-
pression of glucose production during the
clamp was signiﬁcantly lower after the HF
intervention compared with HG (P =
0.015), as also shown by the higher ratio
of endogenous production during the
clamp at baseline (P = 0.009), whereas
there was no difference among HG and
MF or HS (compare Fig. 1). This shows a
signiﬁcant decrease in hepatic insulin sen-
sitivity after relatively small amounts of
daily fructose consumption. In contrast,
no signiﬁcant differences among diets
were seen in glucose metabolic clearance
rate (i.e., insulin-mediated glucose clear-
ance), which is a parameter of whole-body
insulin sensitivity. Mean glucose levels dur-
ing the baseline measurements and the
clamp were kept in the same range.
Also reported in Table 1 are the fast-
ing metabolic characteristics (glucose, in-
sulin, C-peptide, lipids) of the subjects
after each intervention. Fasting levels of
glucose, insulin, and C-peptide did not
differ signiﬁcantly between HG and any
of the other interventions. Compared
with the HG intervention, LDL choles-
terol and total cholesterol were signiﬁ-
cantly higher after the MF, HF, and HS
interventions (P , 0.05). Furthermore,
the free fatty acid concentration was in-
creased after MF compared with HG
(P = 0.033), with a trend toward higher
values after HF and HS, albeit not signif-
icant. No differences were seen among
the interventions for HDL cholesterol or
triglycerides.
Compared with HG (2.02 6 2.28
ng/mL) leptin concentrations were signif-
icantly lower after MF (1.26 6 1.22, P =
0.012) and HF (1.376 2.54 , P = 0.012),
whereas the difference compared to HS
(1.71 6 2.99) was not signiﬁcant.
Dietary intake was assessed at base-
line and after each of the four interven-
tions. The consumption of energy,
macronutrients, ﬁber, and the different
sugars are reported in Table 3. Energy in-
take and the percentage of energy from
fat, carbohydrates, and protein did not
differ signiﬁcantly between HG and the
other interventions, and neither did ﬁber
intake. However, protein intake was sig-
niﬁcantly lower in all interventions, ex-
cept for HS, compared with baseline,
whereas fat intake was signiﬁcantly lower
in the MF and the HS interventions, again
compared with baseline. Carbohydrate
intake was higher in the HF, HG, and
HS interventions comparedwith baseline,
but the differences were not signiﬁcant.
The consumption of the individual sugars
varied according to the interventions.
CONCLUSIONSdThis study has in-
vestigated the effect of SSBs containing
fructose or sucrose compared with those
containing glucose and has resulted in
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two important ﬁndings: 1) Compared
with HG, suppression of endogenous glu-
cose production is reduced after the HF
diet during the euglycemic-hyperinsuline-
mic clamp, indicating reduced hepatic in-
sulin sensitivity after the HF diet, and 2)
after all diets containing fructose (MF,
HF, and HS), total and LDL cholesterol
were elevated compared with HG.
Glucose and fructose have a similar
caloric content, but intermediary fructose
metabolism has unique features. After a
dietary fructose load, fructose is rapidly
cleared from the plasma and efﬁciently
metabolized in the liver in an insulin-
independent manner (2). While glucose
metabolism via hexokinase and glycolysis
is tightly regulated by the energy status of
the cell and insulin levels, fructose metab-
olism via fructokinase bypasses these reg-
ulatory steps. Hence, rapid breakdown of
Table 1dAnthropometric characteristics as well as fasting glucose, insulin, C-peptide, and lipid concentrations of all subjects after each
of the four 3-week interventions
HG MF HF HS
80 g glucose/day 40 g fructose/day 80 g fructose/day 80 g sucrose/day
n = 9 n = 8 n = 9 n = 9
Anthropometrics*
Weight (kg) 74.1 6 7.1 72.0 6 7.7‡ 72.3 6 6.9‡ 73.4 6 7.1
Height (m) 1.80 6 0.08 1.80 6 0.08 1.80 6 0.08 1.80 6 0.08
BMI (kg/m2) 22.8 6 1.4 22.3 6 1.5‡ 22.3 6 1.3‡ 22.6 6 1.1
Waist circumference (cm) 83.3 6 6.2 83.1 6 6.1 82.9 6 6.1‡ 83.3 6 5.8
Body fat (%) 16.8 6 2.8 16.7 6 2.5 15.8 6 2.2‡ 16.3 6 2.0
Body fat (kg) 12.5 6 3.3 12.2 6 3.0 11.3 6 2.0‡ 12.1 6 2.5
Fasting glucose metabolism*
Fasting glucose (mmol/L) 4.24 6 0.26 4.29 6 0.33 4.33 6 0.26 4.32 6 0.28
Insulin (pmol/L) 105.4 6 36.2 89.6 6 22.0 113.8 6 37.3 105.1 6 20.4
C-peptide (pmol/L) 548.9 6 127.5 499.4 6 86.4 535.6 6 119.2 512.2 6 93.6
Lipids
Cholesterol (mmol/L)
Total* 3.48 6 0.69 3.65 6 0.59‡ 3.72 6 0.68‡ 3.76 6 0.77‡
HDL† 1.16 6 0.23 1.18 6 0.21 1.21 6 0.28 1.22 6 0.23
LDL† 1.85 6 0.57 2.03 6 0.54‡ 2.02 6 0.57‡ 2.08 6 0.68‡
Triglycerides (mmol/L)† 0.77 6 0.40 0.65 6 0.58 0.79 6 0.41 0.71 6 0.31
Free fatty acids (mmol/L)* 419.3 6 236.1 578.6 6 230.1‡ 457.0 6 117.3 506.0 6 269.8
*Arithmetic mean 6 SD. †Geometric mean 6 SD. ‡P , 0.05 compared with HG (multiple linear regression with Bonferroni correction for three comparisons).
Table 2dGlucose metabolism during the clamp in all subjects after each of the four 3-week interventions
HG MF HF HS
80 g glucose/day 40 g fructose/day 80 g fructose/day 80 g sucrose/day
n = 9 n = 8 n = 9 n = 9
Glucose concentrations
Glucose baseline*(mmol/L) 4.30 6 0.23 4.17 6 0.17 4.34 6 0.28 4.48 6 0.50
Glucose clamp†(mmol/L) 4.50 6 0.19 4.40 6 0.40 4.71 6 0.42 4.51 6 0.28
Hepatic suppression
Clamp (%) 70.3 6 10.5 72.3 6 21.9 59.4 6 11.0‡ 72.7 6 12.1
Endogenous glucose production rate
Clamp (mmol/kg/min) 3.15 6 1.17 3.49 6 2.06 4.17 6 1.37 3.25 6 1.00
Baseline (mmol/kg/min) 10.53 6 0.99 10.42 6 1.01 10.23 6 1.52 10.64 6 1.10
Clamp/baseline 0.30 6 0.10 0.31 6 0.18 0.41 6 0.11‡ 0.30 6 0.07
Metabolic clearance rate (glucose)
Clamp (mL/kg/min) 5.53 6 1.43 5.60 6 2.25 5.71 6 2.58 5.67 6 1.62
Baseline (mL/kg/min) 2.52 6 0.22 2.53 6 0.31 2.41 6 0.30 2.47 6 0.42
Clamp/baseline 2.20 6 0.55 2.28 6 1.04 2.37 6 0.98 2.29 6 0.45
Total ﬂux (Ra)
Clamp (mmol/kg/min) 24.6 6 6.05 24.2 6 7.71 26.1 6 10.50 25.1 6 6.66
Baseline (mmol/kg/min) 10.7 6 1.00 10.6 6 1.02 10.4 6 1.53 10.8 6 1.11
Clamp/baseline 2.30 6 0.56 2.33 6 0.87 2.56 6 1.00 2.31 6 0.49
All values are the arithmeticmean6 SD. Glucose kinetics are calculated in near steady state at the end of the tracer equilibration period (baseline period) and the clamp
period as described in RESEARCHDESIGN ANDMETHODS. *Mean value at the end of the tracer equilibration period (baseline) at 150, 165, and 180 min. †Mean value at the
end of the 2-h clamp period at 90, 105, and 120 min. ‡P, 0.05 compared with HG (multiple linear regression with Bonferroni correction for three comparisons).
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fructose into trioses leads to high ﬂuxes
through the downstream steps of the gly-
colytic pathway, generating, for example,
precursors and substrates for de novo li-
pogenesis. Fructose ingestion also affects
lipid metabolism via enhanced and ex-
tended activity of regulator proteins (e.g.,
sterol regulatory element-binding protein-
1c for de novo lipogenesis) (1,8,15,16).
Several studies have shown that sup-
plementation with high amounts of fruc-
tose, associated with excess energy intake,
induces features similar to those encoun-
tered in themetabolic syndrome. Themost
striking effect is an increase in fasting
and postprandial triglycerides, which can
be explained by a stimulation of hepatic
de novo lipogenesis (8,17), a stimulation
of VLDL-triglyceride secretion, and a
decreased VLDL-triglyceride clearance
(18,19). In addition, several studies have
reported a mildly impaired hepatic insulin
sensitivity, as indicated by an increase in
fasting hepatic glucose production or by a
blunted suppression of glucose produc-
tion during hyperinsulinemia or a deposi-
tion of ectopic fat in liver cells (7,17,20).
In the current study, we observed a
signiﬁcant decrease in hepatic insulin sen-
sitivity even with relatively small amounts
of daily fructose consumption. This was
documented by using an insulin clamp
at low insulin infusion rates, which in-
completely suppressed hepatic glucose
production. In addition, care was taken to
have a long tracer infusion time beforemea-
surement to avoid erroneous results linked
to incomplete tracer equilibration, which
may explain why similar results were not
observedwith former experiments (6). This
clearly indicates that hepatic insulin sensi-
tivity is exquisitely sensitive to fructose in-
take. The mechanisms underlying these
effects remain unknown but may involve
a stimulation of gluconeogenesis and in-
creased glycogen stores, or may be related
to hepatic lipotoxicity.
In contrast to this impaired hepatic
insulin sensitivity, whole-body (presum-
ably essentially muscle) insulin sensitivity
was not signiﬁcantly altered by fructose-
containing drinks. This is consistent with
other studies that used higher amounts of
fructose (7,17) but may appear at odds
with the observation that high fructose
intakes can impair glucose tolerance.
This strongly suggests that this impaired
glucose tolerance is explained by im-
paired suppression of hepatic glucose out-
put rather than bymuscle insulin resistance,
at least with short-term high-fructose diets.
It remains possible, however, that fructose
administration over longer periods of time
may also alter muscle insulin sensitivity,
possibly through a progressive deposition
of ectopic fat in skeletal muscle, as shown
by Lê et al. (7).
In contrast to other studies (6,21), we
did not observe a signiﬁcant increase in
plasma triglyceride concentrations. This
is most likely related to the relatively
low amount of fructose administered in
Figure 1dHepatic suppression of glucose production (%) after 3 weeks’ consumption of different
SSBs (HG: 80 g glucose/day, MF: 40 g fructose/day, HF: 80 g fructose/day, HS: 80 g sucrose/day).
*P , 0.05 compared with HG. Values are means 6 1 SD.
Table 3dDietary intake of all subjects at baseline and after each of the four 3-week interventions
HG MF HF HS
Baseline 80 g glucose/day 40 g fructose/day 80 g fructose/day 80 g sucrose/day
n = 9 n = 9 n = 8 n = 9 n = 9
Energy (kcal/day) 2,108 6 469 2,187 6 497 1,830 6 766 2,338 6 335 2,141 6 349
Carbohydrates, % 49 6 8.5 54 6 5.3 47 6 18.5 56 6 5.0 54 6 6.1
Protein, % 17 6 3.5 14 6 1.7* 13 6 5.4* 13 6 2.0* 16 6 3.4
Fat, % 34 6 6.9 31 6 5.1 29 6 11.7* 31 6 4.3 30 6 5.8*
Free fructose (g/day) 14.9 6 6.5 7.8 6 6.3* 51.2 6 5.9*† 88.2 6 4.8*† 9.5 6 4.9
Total fructose (g/day) 40.3 6 15.4 27.7 6 11.2*† 77.3 6 13.9*† 110.2 6 8.8*† 71.5 6 17.3*†
Free glucose (g/day) 13.8 6 5.8 89.3 6 4.7*† 7.8 6 3.9† 7.2 6 3.5*† 8.2 6 4.0†
Total glucose (g/day) 39.2 6 14.9 109.2 6 7.8*† 33.9 6 14.7*† 29.2 6 8.3*† 68.5 6 16.1*†
Sucrose (g/day) 50.8 6 23.4 39.6 6 14.9 52.2 6 27.4 44.0 6 15.1 117.1 6 21.4*†
Fibers (g/day) 22.7 6 11.0 17.5 6 8.4 18.3 6 5.9 19.8 6 7.0 16.5 6 5.9
All values are shown as the arithmetic mean6 SD. *P, 0.05 compared with baseline (multiple linear regression with Bonferroni correction for four comparisons).
†P , 0.05 compared with HG (multiple linear regression including MF, HF, HG and HS with Bonferroni correction for three comparisons).
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the current study. A meta-analysis (22)
showed fasting triglyceride concentra-
tions increase with daily fructose intake
above 100 g/day (i.e., somewhat higher
than used in the present experiments).
However, interestingly, we found an in-
crease in total and LDL-cholesterol con-
centrations after the HF, MF, andHS diets
compared with HG.
Similarly, the study by Bantle et al.
(21) revealed differences in total and LDL-
cholesterol between fructose and glucose
diets after a study duration of 4weeks, but
they were no longer signiﬁcant after 6
weeks, which was the study end point.
At this point, the only parameter that
did differ between the glucose and fruc-
tose diets was triglyceride concentration
in men (21). However, despite similar
amounts of fructose and glucose, the
study population in their trial was not
necessarily comparable to the one in the
current study. All subjects in our study
were aged between 21 and 25 years,
whereas in the Bantle et al. study, half of
the subjects were aged older than 40
years. Further, the mean BMI of our
healthy volunteers was 22.3 kg/m2 at
baseline but was 24.7 and 25.8 kg/m2 in
the subjects aged younger and older than
40 years of age, respectively, in the Bantle
et al. (21) study.
Following along the same line, an-
other recent study investigating the effect
of different sugars on lipid metabolism
reported results comparable to ours, de-
spite methodologic differences (25% of
energy requirements given as SSB, dura-
tion 2 weeks). This group observed in-
creased concentrations of LDL cholesterol
and also of 24-h triglyceride area under
the curve (a parameter we did not assess)
after fructose and high-fructose corn
syrup, but not after glucose consumption,
whereas fasting triglycerides were similar
after all interventions (23).
A special feature of the current study
is that it provided a direct comparison of
the effects of fructose-containing drinks
to glucose alone. Only few studies have
performed such a direct comparison.
Stanhope et al. (8) found an increase in
fasting glucose and a decrease in insulin
sensitivity after a 10-week intervention
with fructose-containing beverages but
not after glucose-containing beverages.
However, the energy provided by the
fructose and glucose beverages in their
study accounted for 25% of total energy
intake. In our study, diminished hepatic
insulin sensitivity could be seen despite a
considerably lower amount of sugar given
(15% of baseline energy intake) and a
much shorter study duration. This indi-
cates that already relatively low amounts
of fructose over a short period of timemay
negatively affect glucose metabolism,
even in healthy lean subjects. In disagree-
ment with our results, recent studies by
Silbernagel et al. (24) and Ngo Sock et al.
(20) found similar effects of high-glucose
and high-fructose diets with regard to in-
sulin sensitivity determined by an oral
glucose tolerance test (24) or to intrahe-
patic fat content (20); however, there
was a signiﬁcant increase in fasting tri-
glyceride concentrations with fructose
only.
Compared with the glucose interven-
tion, we found signiﬁcantly lower weight
and BMI after theMF andHF intervention
and signiﬁcantly lower body fat and waist
circumference after HF only. Even though
the differences were relatively small, the
ﬁnding was consistent over the different
anthropometric measurements and could
not be explained by higher energy intake
during the HG intervention or by reduced
physical activity. One previous study
comparing weight and fat changes after
HF and HG diets found that, even though
overall weight gain was similar, fructose
induced more gain in intra-abdominal
adipose tissue, whereas glucose led to
increased subcutaneous adipose tissue
(8). The duration of the interventions in
that study, however, was 10 weeks, and
25% of energy requirements were pro-
vided by sugar. We did not distinguish
between intra-abdominal and subcutane-
ous adipose tissue in our study and can
therefore not be sure what the changes we
have observed were attributable to. How-
ever, previous studies have shown that
leptin is mainly secreted in subcutaneous
adipose tissue (25,26). Thus, the in-
creased secretion of leptin after HG com-
pared with HF and MF we have observed
also points toward an increase in subcu-
taneous adipose tissue after this interven-
tion. The small sample size in our study
and the relatively short study duration
may have blunted other changes seen in
previous studies.
A limitation of the current study may
be the relatively short duration of the
interventions and the moderate amount
of sugars given. However, our aim was to
study the effect of the different sugars in
amounts that are likely to be consumed
in normal life. That we did see certain
effects already at this level and after 3
weeks seems to justify our decision. An-
other limitation is the lack of baseline
measurements before each of the inter-
ventions. Still, based on the complexity of
the method used and the already high
subject burden, we decided against them.
However, to control for possible baseline
differences,weused a randomized crossover
design and controlled for the order of
interventions in the statistical analysis.
In conclusion, this study shows
that, with regard to glucose metabolism
and, speciﬁcally, hepatic insulin sensi-
tivity, fructose, even inmoderate amounts,
seems to be more harmful than the same
amount of glucose. Furthermore, all
fructose-containing drinks (including
sucrose) showed signiﬁcant effects on
the lipid proﬁle compared with glucose.
However, anthropometric measure-
ments pointed toward higher adiposity
after the glucose intervention, even
though differences were small. Thus,
even when consumed in moderate
amounts and over a limited period of
time, SSB, especially those containing
fructose, can result in alterations of he-
patic glucose metabolism and lipid pro-
ﬁle in healthy young men, which may
possibly be associated with increased
cardiometabolic risk. Further research
will be needed to better understand the
underlying mechanisms, speciﬁcally
with regard to the lipid metabolism
and also to understand other inﬂuenc-
ing factors such as age, sex, or genetic
predisposition.
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